The Instituto de Salud Pública (ISP), through ANAMED, coordinates pharmacovigilance for medicines in Chile.
Core official resources
- Pharmacovigilance hub — national PV information, reporting and safety communications.
- RAM and ESAVI notification — current reporting routes and the Sistema de Vigilancia Integrado (SVI).
- Industry pharmacovigilance — requirements for holders of sanitary registrations.
- SVI manuals and supporting material — operational registration and reporting instructions.
- Pharmacovigilance bulletins — national safety analyses and regulatory communications.
Important national distinction
ISP states that SVI is the official reporting route for suspected medicine and vaccine adverse events. Registration holders must report Chilean suspected ADRs they become aware of; serious, unexpected or recent-market cases are prioritised and are subject to a maximum 15-calendar-day reporting period under the published ISP instructions.